Translational Applications of Artificial Intelligence and Machine Learning for Diagnostic Pathology in Lymphoid Neoplasms: A Comprehensive and Evolutive Analysis
Metadatos
Afficher la notice complèteAuteur
Moran Sánchez, Julia; Santisteban Espejo, Antonio Leopoldo; Martín Piedra, Miguel Ángel; Pérez Requena, José; García Rojo, MarcialEditorial
MDPI
Materia
Artificial intelligence Hematopathology Lymphoid neoplasms Digital image analysis Machine Learning
Date
2021Referencia bibliográfica
Moran-Sanchez, J.; Santisteban-Espejo, A.; Martin-Piedra, M.A.; Perez-Requena, J.; GarciaRojo, M. Translational Applications of Artificial Intelligence and Machine Learning for Diagnostic Pathology in Lymphoid Neoplasms: A Comprehensive and Evolutive Analysis. Biomolecules 2021, 11, 793. https://doi.org/10.3390/ biom11060793
Patrocinador
Andalusia Health System - RH-0145-2020; EU FEDER ITI Grant for Cadiz Province PI-0032-2017Résumé
Genomic analysis and digitalization of medical records have led to a big data scenario
within hematopathology. Artificial intelligence and machine learning tools are increasingly used to
integrate clinical, histopathological, and genomic data in lymphoid neoplasms. In this study, we
identified global trends, cognitive, and social framework of this field from 1990 to 2020. Metadata
were obtained from the Clarivate Analytics Web of Science database in January 2021. A total of 525
documents were assessed by document type, research areas, source titles, organizations, and countries. SciMAT and VOSviewer package were used to perform scientific mapping analysis. Geographical distribution showed the USA and People’s Republic of China as the most productive
countries, reporting up to 190 (36.19%) of all documents. A third-degree polynomic equation predicts that future global production in this area will be three-fold the current number, near 2031.
Thematically, current research is focused on the integration of digital image analysis and genomic
sequencing in Non-Hodgkin lymphomas, prediction of chemotherapy response and validation of
new prognostic models. These findings can serve pathology departments to depict future clinical
and research avenues, but also, public institutions and administrations to promote synergies and
optimize funding allocation.